Furthermore, among 8060 Taiwanese people with type 2 diabetes and COPD, users of the GLP-1 receptor agonist with a median follow-up duration of 2.51 years, the risk of pulmonary complication was significantly lower than in non-users. This evidence concerns the gene GLP1R and chronic obstructive pulmonary disease.